Literature DB >> 1571547

Direct detection of activated protein C in blood from human subjects.

A Gruber1, J H Griffin.   

Abstract

The antithrombotic enzyme, activated protein C (APC) was measured in blood using an enzyme capture assay (ECA). The ECA involved (1) collection of blood into anticoagulant containing a reversible inhibitor of the enzyme, (2) specific affinity capture of the enzyme by an immobilized antibody that does not inhibit the enzyme, (3) removal of the reversible inhibitor by washing, and (4) direct assay of the captured enzyme's amidolytic activity. The ECA for APC used benzamidine for inhibition, anti-PC light-chain murine monoclonal antibody for capture, and the oligopeptide substrate S-2366 for enzyme assay. The sensitivity of this assay was 5 pmol/L (0.3 ng/mL) APC. The APC activity in normal pooled plasma corresponded to the amidolytic activity of 38 pmol/L (2.26 +/- 0.2 ng/mL) purified human plasma-derived APC in the ECA. APC levels in 41 normal donors ranged from 64% to 143%, averaging 104.9% +/- 19.6% (SD). Thus, APC is a measurable and normal component of circulating human blood, and this ECA may be useful for identifying APC deficiency. Moreover, similar ECAs for other enzymes in the circulation may be useful.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1571547

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  29 in total

1.  Laboratory Measurement of Thrombin Activity--What Every Clinician Scientist Needs to Know.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

2.  The functional significance of the autolysis loop in protein C and activated protein C.

Authors:  Likui Yang; Chandrashekhara Manithody; Alireza R Rezaie
Journal:  Thromb Haemost       Date:  2005-07       Impact factor: 5.249

3.  Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates.

Authors:  András Gruber; Ulla M Marzec; Leslie Bush; Enrico Di Cera; José A Fernández; Michelle A Berny; Erik I Tucker; Owen J T McCarty; John H Griffin; Stephen R Hanson
Journal:  Blood       Date:  2007-01-16       Impact factor: 22.113

4.  Anticoagulant synergism of heparin and activated protein C in vitro. Role of a novel anticoagulant mechanism of heparin, enhancement of inactivation of factor V by activated protein C.

Authors:  J Petäjä; J A Fernández; A Gruber; J H Griffin
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

5.  Circulating activated protein C in thrombophilia carriers.

Authors:  Thijs E van Mens; Joost C M Meijers; Saskia Middeldorp
Journal:  J Thromb Thrombolysis       Date:  2017-04       Impact factor: 2.300

6.  Engineering the proteolytic specificity of activated protein C improves its pharmacological properties.

Authors:  David T Berg; Bruce Gerlitz; Jing Shang; Tommy Smith; Paula Santa; Mark A Richardson; Ken D Kurz; Brian W Grinnell; Ken Mace; Bryan E Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-01       Impact factor: 11.205

Review 7.  Can adjunctive therapies augment the efficacy of endovascular thrombolysis? A potential role for activated protein C.

Authors:  Arun Paul Amar; Abhay P Sagare; Zhen Zhao; Yaoming Wang; Amy R Nelson; John H Griffin; Berislav V Zlokovic
Journal:  Neuropharmacology       Date:  2017-09-18       Impact factor: 5.250

8.  Activated Protein C Drives the Hyperfibrinolysis of Acute Traumatic Coagulopathy.

Authors:  Ross A Davenport; Maria Guerreiro; Daniel Frith; Claire Rourke; Sean Platton; Mitchell Cohen; Rupert Pearse; Chris Thiemermann; Karim Brohi
Journal:  Anesthesiology       Date:  2017-01       Impact factor: 7.892

9.  Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V.

Authors:  B Dahlbäck; B Hildebrand
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

10.  Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates.

Authors:  S R Hanson; J H Griffin; L A Harker; A B Kelly; C T Esmon; A Gruber
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.